PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home »

Psychiatric Times. Vol. 29 No. 3
Pages: 1  2  3  4  
Previous
VANGUARD ISSUES IN PSYCHIATRY 

A Delicate Brain: Ethical and Practical Considerations for the Use of Medications in Very Young Children

By Stacy S. Drury, MD, PhD and Mary Margaret Gleason, MD | February 28, 2012
Dr Drury is Assistant Professor of Psychiatry and Behavioral Science and Assistant Professor of Pediatrics, Tulane University School of Medicine, New Orleans. Dr Gleason is Assistant Professor of Psychiatry and Behavioral Science and Assistant Professor of Pediatrics at Tulane University School of Medicine. The authors report no conflicts of interest concerning the subject matter of this article.

To move forward will require a concerted effort across multiple systems. We must address the critical shortage of child mental health providers at all levels. Federal efforts to address this shortage, such as the currently approved but as yet unfunded Child Health Care Crisis Relief Act (H.R. 1932/S. 999), would provide student loan repayment for child health care providers and training stipends directly to institutions to support the training of child psychiatrists, psychologists, and social workers. Efforts to get this program funded are needed. Mental health care policies must be reformed to provide adequate reimbursement for the comprehensive assessments recommended by clinical guidelines as well as to provide for the implementation of psychotherapeutic evidence-based modalities in young children.

Treatment of parental mental health problems, a well-established approach to reducing child mental health symptoms, is promised through the Affordable Health Care Act and must be linked to child mental health care services. Existing guidelines for the use of psychotropic medications in young children should be implemented. The Best Pharmaceuticals for Children Act has called for more research on both the developmental neurobiological impact of stimulants and antipsychotics and the long-term efficacy and safety of these medications. Implementation of these recommendations would make substantial progress toward ending both the historically disproportionate lack of information on treating young children with these medications and the inadequate approach toward young children’s psychopathology. Effective, early intervention and appropriate support for and treatment of the caregivers of these vulnerable children will improve short-term outcomes and also may provide positive lifelong benefits.

Pages: 1  2  3  4  
Previous
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by Renata Pilatova | May 11, 2012 12:41 PM EDT

As a pediatrician taking care of children with mental health issues (in Alexandria, LA), I wholeheartedly agree

by The Editors | March 14, 2012 11:22 AM EDT

The following comment is by Manuel Mota-Castillo, MD:

There is lot to say about this well-written paper that touches a very important issue. I would bet on the side of good intentions inspiring the authors to present the facts (and several myths) in a way that, unfortunately could lead the readers to make false assumptions.

Since I stated the inclusion of myths I will start with the first one: Severe Mental Illness goes away.

We certainly can cure obsessions and phobias with CBT but this effective technique only helps the treatment of major mental disorders such as schizophrenia, autism and bipolar spectrum disease. Furthermore finding a psychotherapist specialized in CBT that accept Medicaid patients is as difficult as wining the Power Ball lottery.

The authors also use "revealed truths"elevated to such a distinguished status by the old trick of repetition. One example is the assertion that "when two medications are combined the risk of developing…"in reference to the possibility of harming a developing brain with psychotropic drugs. This is true if we look at the issue as mathematicians, but what happens when we walk down to the trenches and face a patient that has more chances of developing side effects from 2 milligrams of risperidone than if we only prescribe 1 mg and add lamotrigine, lithium or valproic acid to treat the symptoms of bipolar illness?

They also refer to the "lack of efficacy for the use of psychotropic medications in children" in complete disregard of the fact that this perceived failure in the pediatric population is due to the widespread misdiagnosis of disruptive behaviors, anxieties, elevated moods and even psychosis as reason to label a child with the flavor of the decade, ADHD.

Here is a real case: 50 pounds boy on 80 mg of amphetamine salts having auditory hallucinations, displaying a very aggressive behavior and staying up all night. His pediatrician referred him to a psychiatrist when the doctor discovered that his patient is adopted and that his biological parents have severe mental illness. The C & A psychiatrist that treated him before me kept the ADHD diagnosis (and the astronomical dose of amphetamine) and added a small amount of risperidone at night, clonidine in the morning and a twice a day dosing of valproic acid. The poor child, who never had ADHD was biting his lips and showing serious facial tics…but the stimulant was continued. How can we call this a failure of the mood stabilizers?...how come the experts in this field trust statistics that rely on studies of bipolar patients treated for years with antidepressants as cases of Treatment-Resistant Depression and continued on these drugs after the real diagnosis was made? How the MTA became so relevant when its data is contaminated with cases of Oppositional-Defiant Disorder which is not a real disease but a symptom?

In the past I used to say that when I practiced pediatrics I never heard a mother complaining of the "terrible side effects of chemotherapy" when her child was in treatment for Leukemia. Now, with my youngest daughter with Lupus it really feels close to home when I hear about side effects from "dangerous drugs." Still, what are my choices?

I wonder if society in general has ever considered that a serious mental illness can be as lethal as a major physical condition and it should be treated as such.

A few hours ago I said to one of my new patients "for the past 20 years doctors have been aiming at the wrong target." You don't have fatigue; you are tired because, as you just told me, you never had a full-night sleep. She is another "failure" of medications to control her anxiety and depression because her real problem is a racing mind, poor anger control and impulsivity.

I would like to conclude with a simple question: Could it be more productive to worry about making a correct diagnosis than getting anxious about side effects that, when present are the necessary price to pay for keeping a life-threatening illness at bay?

Manuel Mota-Castillo, MD
Lake Mary, FL
www.psychiatricanswers.com
Youtube video: ADHD a real disease but a false epidemic

Also in this Special Report

Introduction: Controversies and Evolving Issues

Condemning Torture and Abuse: A Call to Action

A Delicate Brain: Ethical and Practical Considerations for the Use of Medications in Very Young Children

Who Was Karen Horney?

Antipsychotics for Behavioral Disturbance in Dementia? A Clinical Conundrum

Neuroscientific Mirages: Are We No More Than Our Brains?

Are Animal Models Relevant in Modern Psychiatry?

Enlightenment and Dimmed Enlightenment

VANGUARD ISSUES IN PSYCHIATRY

Introduction: Controversies and Evolving Issues

Condemning Torture and Abuse: A Call to Action

A Delicate Brain: Ethical and Practical Considerations for the Use of Medications in Very Young Children

Who Was Karen Horney?

Antipsychotics for Behavioral Disturbance in Dementia? A Clinical Conundrum

Enlightenment and Dimmed Enlightenment

Are Animal Models Relevant in Modern Psychiatry?





References

1. Steinberg-Epstein R, Book T, Wigal SB. Controversies surrounding pediatric psychopharmacology. Adv Pediatr.2011;58:153-179.
2. Egger HL, Angold A. Common emotional and behavioral disorders in preschool children: presentation, nosology, and epidemiology. J Child Psychol Psychiatry.2006;47:313-337.
3. Hood KK, Eyberg SM. Outcomes of parent-child interaction therapy: mothers’ reports of maintenance three to six years after treatment. J Clin Child Adolesc Psychol. 2003;32:419-429.
4. Cohen JA, Mannarino AP. A treatment outcome study for sexually abused preschool children: initial findings [published correction appears in J Am Acad Child Adolesc Psychiatry.1996;35:835]. J Am Acad Child Adolesc Psychiatry.1996;35:42-50.
5. Lieberman AF, Ghosh Ippen C, Van Horn P. Child-parent psychotherapy: 6-month follow-up of a randomized controlled trial. J Am Acad Child Adolesc Psychiatry.2006;45:913-918.
6. Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA.2000;283:1025-1030.
7. Pear R. White House seeks to curb pills used to calm the young. New York Times.March 20, 2000.
8. Shute N, Locy T, Pasternak D, et al. The perils of pills. The psychiatric medication of children is dangerously haphazard. US News World Rep. 2000;128:44-50.
9. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry.2005;44:548-556.
10.Cooper WO, Hickson GB, Fuchs C, et al. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med.2004;158:753-759.
11. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children [published correction appears in Am J Psychi­atry.2006;163:942]. Am J Psychiatry.2006;163:579-585.
12. Zito JM, Safer DJ, Valluri S, et al. Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. J Child Adolesc Psychopharmacol.2007;17:195-203.
13. Constantine RJ, Tandon R, McPherson M, Andel R. Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under 6 years old who received antipsychotic treatment in Florida’s Medicaid program. J Child Adolesc Psychopharmacol.2011;21:79-84.
14. Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry.2010;49:13-23.
15. McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder [published correction appears in J Am Acad Child Adolesc Psychiatry.2007;46:786]. J Am Acad Child Adolesc Psychiatry.2007;46:107-125.
16. Ellis AR. The administration of psychotropic medication to children ages 0-4 in North Carolina: an exploratory analysis. N C Med J.2010;71:9-14.
17. Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry.2007;46:1532-1572.
18. Food and Drug Administration. Best Pharmaceuticals for Children Act of 2002. January 2002. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049876.htm. Accessed February 14, 2012.
19.Laughren TP. Regulatory issues in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry.1996;35:1276-1282.
20. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD [published correction appears in J Am Acad Child Adolesc Psychiatry.2007;46:141]. J Am Acad Child Adolesc Psychiatry.2006;45:1284-1293.
21.Llorente-Berzal A, Mela V, Borcel E, et al. Neurobehavioral and metabolic long-term consequences of neonatal maternal deprivation stress and adolescent olanzapine treatment in male and female rats. Neuropharmacology. 2011 Jul 28; [Epub ahead of print].
22. Moll GH, Hause S, Rüther E, et al. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol.2001;11:15-24.
23. Penner MR, McFadyen MP, Pinaud R, et al. Age-related distribution of c-fos expression in the striatum of CD-1 mice after acute methylphenidate administration. Brain Res Dev Brain Res.2002;135:71-77.
24. Gray JD, Punsoni M, Tabori N, et al. Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci.2007;27:7196-7207.
25.Findling R, Drury S, Jensen P, Rapoport J; AACAP Committee on Quality Issues. Practice parameter for the use of atypical antipsychotic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry.In press.
26. American Academy of Child and Adolescent Psychiatry. Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry.2009;48:961-973.
27. Spetie L, Arnold LE. Ethical issues in child psychopharmacology research and practice: emphasis on preschoolers. Psychopharmacology (Berl).2007;191:15-26.
28. Leslie LK, Raghavan R, Zhang J, Aarons GA. Rates of psychotropic medication use over time among youth in child welfare/child protective services. J Child Adolesc Psychopharmacol.2010;20:135-143.


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • The Moral Struggles of Practicing Psychiatrists
  • Grief and Depression: The Sages Knew the Difference
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Grief and Depression: The Sages Knew the Difference
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • The Role of Biological Tests in Psychiatric Diagnosis
  • You Are—And Your Mood Is—What You Eat
  • Experts Discuss Changes, Updates in DSM-5
  • The Paradox of Choice: When More Medications Mean Less Treatment
  • Will Your Clinical Records Support You in Court?
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Grief and Depression: The Sages Knew the Difference
  • Psychiatry and the Myth of “Medicalization”
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • NIMH vs DSM 5: No One Wins, Patients Lose
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • The Paradox of Choice: When More Medications Mean Less Treatment
  • Experts Discuss Changes, Updates in DSM-5
  • New Insight Into the Neurobiology of Depression
  • Tie One On for Patients
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
SearchMedica SEARCH RESULT

Find peer-reviewed literature and websites for practicing medical professionals

CME on Display
Evidence on Display
Guidelines on Display
Patient Education on Display
Clinical Trials on Display
Practical Articles on Display
Research and Reviews on Display
All "Display" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy